These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9893628)

  • 1. Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma.
    Fridrik MA; Jäger G; Kienzer HR; Hausmaninger H; Oppitz P; Krieger O; Zabernigg A; Lang A; Neubauer M; Weidinger G; Schiller L; Seewann HL; Chott A; Linkesch W
    Eur J Cancer; 1998 Sep; 34(10):1560-4. PubMed ID: 9893628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
    Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T
    J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
    Rummel MJ; Chow KU; Karakas T; Jäger E; Mezger J; von Grünhagen U; Schalk KP; Burkhard O; Hansmann ML; Ritzel H; Bergmann L; Hoelzer D; Mitrou PS
    Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma.
    Tulpule A; Schiller G; Harvey-Buchanan LA; Lee M; Espina BM; Khan AU; Boswell W; Nathwani B; Levine AM
    Cancer; 1998 Dec; 83(11):2370-6. PubMed ID: 9840537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy.
    Brugiatelli M; Holowiecka B; Dmoszynska A; Krieger O; Planinc-Peraica A; Labar B; Callea V; Morabito F; Jaksic B; Holowiecki J; Lutz D
    Ann Hematol; 1996 Aug; 73(2):79-84. PubMed ID: 8774616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cladribine for untreated or early low-grade non-Hodgkin's lymphoma.
    Liliemark J; Martinsson U; Cavallin-Ståhl E; Svedmyr E; Porwit A; Strömberg M; Juliusson G
    Leuk Lymphoma; 1998 Aug; 30(5-6):573-81. PubMed ID: 9711919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma.
    Róbak T; Gora-Tybor J; Krykowski E; Walewski JA; Borawska A; Pluźańska A; Potemski P; Hellmann A; Zaucha JM; Konopka L; Ceglarek B; Durźyński T; Sikorska A; Michalak K; Urasiński J; Opalińska J; Dmoszyńska A; Adamczyk-Cioch MB; Kuratowska Z; Dwilewicz-Trojaczek J; Boguradzki P; Deren M; Maj S; Grieb P
    Leuk Lymphoma; 1997 Jun; 26(1-2):99-105. PubMed ID: 9250793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse.
    Rummel MJ; Chow KU; Jäger E; Hossfeld DK; Bergmann L; Peters HD; Hansmann ML; Meyer A; Hoelzer D; Mitrou PS
    Ann Oncol; 1999 Jan; 10(1):115-7. PubMed ID: 10076731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas.
    Rummel MJ; Chow KU; Jäger E; Leimer L; Hossfeld DK; Bergmann L; Peters HD; Hansmann ML; Meyer A; Hoelzer D; Mitrou PS
    Leuk Lymphoma; 1999 Sep; 35(1-2):129-38. PubMed ID: 10512170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
    Laurencet F; Ballabeni P; Rufener B; Hess U; Cerny T; Fey M; Luthi JM; Plancherel C; Zulian GB;
    Acta Haematol; 2007; 117(1):40-7. PubMed ID: 17095858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
    Kong LR; Huang CF; Hakimian D; Variakojis D; Klein L; Kuzel TM; Gordon LI; Zanzig C; Wollins E; Tallman MS
    Cancer; 1998 Mar; 82(5):957-64. PubMed ID: 9486587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study.
    Takamatsu Y; Suzumiya J; Ogata K; Katayose K; Sasaki H; Ishitsuka K; Kimura N; Tamura K
    J Clin Exp Hematop; 2009 Nov; 49(2):69-75. PubMed ID: 19907111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group.
    Bezwoda W; Rastogi RB; Erazo Valla A; Diaz-Maqueo JC; Pavlovsky S; Morioka H; Resegotti L; Rueckle H; Somoza N; Moreno-Nogueira JA
    Eur J Cancer; 1995 Jun; 31A(6):903-11. PubMed ID: 7646919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study.
    Ogura M; Morishima Y; Kobayashi Y; Uike N; Sugai S; Chou T; Kasai M; Miura I; Murayama T; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Tobinai K;
    Int J Hematol; 2004 Oct; 80(3):267-77. PubMed ID: 15540903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study Group.
    Morton J; Taylor K; Bunce I; Eliadis P; Rentoul A; Moore D; Kelly C; Wright S; Bashford J; Rodwell R; Rooney K; Mulligan S; Firkin F; Dodds A; Parkin J; Lowenthal R; Kimber R; Frost T; Grigg A; Goldstein D; Stone J; Lee N
    Br J Haematol; 1996 Oct; 95(1):110-5. PubMed ID: 8857946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group.
    Tobinai K; Ogura M; Hotta T; Kobayashi Y; Narabayashi M; Suzuki R; Kinoshita T; Kozuru M; Uike N; Ohashi Y
    Jpn J Clin Oncol; 1997 Jun; 27(3):146-53. PubMed ID: 9255268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.
    Hoffman M; Tallman MS; Hakimian D; Janson D; Hogan D; Variakogis D; Kuzel T; Gordon LI; Rai K
    J Clin Oncol; 1994 Apr; 12(4):788-92. PubMed ID: 7908690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
    Robak T; Lech-Maranda E; Janus A; Blonski J; Wierzbowska A; Gora-Tybor J
    Leuk Lymphoma; 2007 Jun; 48(6):1092-101. PubMed ID: 17577772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK).
    Betticher DC; Ratschiller D; Hsu Schmitz SF; von Rohr A; Hess U; Zulian G; Wernli M; Tichelli A; Tobler A; Fey MF; Cerny T
    Ann Oncol; 1998 Jul; 9(7):721-6. PubMed ID: 9739437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.